Selective amino acid formulation enhances anion secretion and restores function in cystic fibrosis mutations
SAA enhances chloride secretion through SLC26A9 and partial CFTR rescue in Class I and II mutations. These findings suggest SAA functions as a mutation-agnostic therapy to improve anion secretion and clinical symptoms, particularly in Class I mutations.
Authors
- Sreekala Prabhakaran (ORCID: https://orcid.org/0000-0001-8717-9338)
- Damiano Angoli
- Matthias Salathé (ORCID: https://orcid.org/0000-0001-9092-4861)
- Sadasivan Vidyasagar (ORCID: https://orcid.org/0000-0003-1535-7259)
- Anusree Sasidharan
- Nathalie Baumlin (ORCID: https://orcid.org/0000-0002-5341-6785)
- Astrid Grosche
- Xiaodong Xu (ORCID: https://orcid.org/0000-0002-6473-6637)
Institutions
- University of Florida (US)
- University of Kansas Medical Center (US)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-08-04
- DOI
- https://doi.org/10.3389/fphar.2025.1522130
- Primary Topic
- Cystic Fibrosis Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Rose Foundation for Communities and the Environment
- Yonsei University